Santhera Pharmaceuticals Holding AG
SIX:SANN
Santhera Pharmaceuticals Holding AG
Revenue
Santhera Pharmaceuticals Holding AG
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
S
|
Santhera Pharmaceuticals Holding AG
SIX:SANN
|
Revenue
CHf7.5m
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
ADC Therapeutics SA
NYSE:ADCT
|
Revenue
$69.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
129%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Revenue
$371.2m
|
CAGR 3-Years
709%
|
CAGR 5-Years
160%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Revenue
CHf157.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
Idorsia Ltd
SIX:IDIA
|
Revenue
CHf97.1m
|
CAGR 3-Years
60%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Revenue
CHf33.6m
|
CAGR 3-Years
103%
|
CAGR 5-Years
116%
|
CAGR 10-Years
N/A
|
See Also
What is Santhera Pharmaceuticals Holding AG's Revenue?
Revenue
7.5m
CHF
Based on the financial report for Dec 31, 2022, Santhera Pharmaceuticals Holding AG's Revenue amounts to 7.5m CHF.
What is Santhera Pharmaceuticals Holding AG's Revenue growth rate?
Revenue CAGR 5Y
-20%
The average annual Revenue growth rates for Santhera Pharmaceuticals Holding AG have been -54% over the past three years , -20% over the past five years .